Effects of High-Dose Statin Therapy on Cognitive Functions and Quality of Life in Very High Cardiovascular Risk Patients

Aim. To investigate the effects of intensive lipid-lowering therapy on cognitive functions and quality of life in patients (pts) with very high cardiovascular risk. Material and methods. In 93 pts (58 men, 63.2±9.5 years old with history of clinically evident cardiovascular disease and fasting low-density lipoprotein cholesterol (LDL-C) >1.8 mmol/l or non-high-density lipoprotein cholesterol (non-HDL-C) >2.6 mmol/l the mental status and quality of life were assessed before and after 6 months of therapy with atorvastatin 80 mg/day. The Montreal Cognitive Assessment (MoCA) scale and Questionnaire SF-36 (russian version) were used to evaluate cognitive functions and quality of life. Results. 59 (63%) pts had cognitive dysfunction (less than 26 scores by MoCA scale). We observed significant difference in cognitive status between pts >65 and <65 years (21.1±3.3 vs 25.6±1.8 points, p<0.05) and between pts with and without stroke (22.4±3.1 vs 24.7±2.78 points, p<0.05). Changes of cognitive function were insignificant in all groups. We observed improvement of mean scores in all sections of SF-36 except vitality: physical functioning (PF) from 57.3±26.7 to 62.9±23.4 points, role-physical functioning (RP) from 40.0±27.9 to 47.1±26.2, bodily pain (BP) from 58.9±30.1 to 70.3±25.4, general health (GH) from 51.9±13.6 to 57.4±14.1, social functioning (SF) from 62.5±23.1 to 70.3±25.4 points, role-emotional (RE) from 53.3±39.4 to 61.4±33.1, mental health (MH) from 66.4±15.1 to 71.3±18.2 points (p<0.05 for all trends). Values of PF, RP, GH and RE grew more in <65 years group. Conclusion. 63% of patients with high cardiovascular risk had cognitive impairment. No association between statin use and cognition was found. Intensive lipid-lowering therapy was association significant improvement of quality of life according to SF-36.

статины, интенсивная терапия статинами, когнитивные функции, качество жизни, statins, intensive statin therapy, cognitive functions, quality of life

1. Kuharchuk V. V., Konovalov G. A., Galjavich A. S. et al. Diagnostics and correction of dyslipidaemias in the prevention and treatment of atherosclerosis. Russian recommendations. Revision V. Ateroskleroz i dislipidemii 2012;4:5-61. Russian (Кухарчук В. В., Коновалов Г. А., Галявич А. С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии 2012;4:5-61).

2. Catapano A. L., De Backer G., Wiklund O. et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. Advance Access published August 27, 2016. doi:10.1093/eurheartj/ehw272. http://eurheartj.oxfordjournals.org/content/early/ 2016/08/26/eur-heartj.ehw272.

3. Stone N.J., RobinsonJ. G., Lichtenstein A. H. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129: S1 - S45. doi: 10.1161/01.cir.0000437738.63853.7a.

4. Cholesterol Treatment Trialists' (CTT) Collaboration. Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81. doi: 10.1016/S0140-6736 (10) 61350-5.

5. King D. S., Wilburn A. J., Wofford M. R. et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003;23 (12):1663-1667.

6. Parker B. A., Polk D. M., Rabdiya V. et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. Pharmacotherapy 2010;30 (6):236e - 40e.

7. US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterollowering statin drugs 2012. http://www.fda.gov/Drugs/DrugSafe ty / ucm293101.htm.

8. Brass L. M., Alberts M.J., Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006;97 (8A): 86С-88С. DOI: 10.1016/j.amjcard.2005.12.017

9. Bettermann K., Arnold A. M., Williamson J. et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis 2011; 21 (6):436-444. doi: 10.1016/j.jstrokecerebrovasdis.2010.11.002.

10. Muldoon M. F., Rossouw J. E., Manuck S. B., et al. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism 1993;42:45-56.

11. You H., Lu W., Zhao S. et al. TTe relationship between statins and depression: a review of the literature. Expert Opin Pharmacother 2013;14:1467-1476. doi: 10.1517/14656566.2013.803067.

12. O'Neil A., Sanna L., Redlich C., et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012;10:154. doi: 10.1186/1741-7015-10-154.

13. While A., Keen L. TTe effects of statins on mood: a review of the literature. Eur J Cardiovasc Nurs 2012;11:85-96. doi: 10.1016/ j.ejcnurse.2010.08.008.

14. Golomb B. A., Evans M. A., Dimsdale J. E., et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-1182. doi: 10.1001 /archinternmed.2012.2171.

15. Mikus C. R., Boyle L. J., Borengasser S. J., et al. Simvastatin impairs exercise training adaptation. J Am Coll Cardiol 2013;62:709-714. doi: 10.1016/j.jacc.2013.02.074.

16. http://newpsyhelp.ru/files/MoCA/MoCA.pdf

17. Инструкция по обработке данных, полученных с помощью опросника SF-36. http://therapy.irkutsk.ru/doc/sf36a.pdf

18. Permission for questionnaire SF-36 use. OPTUMINSIGHT NON-COMMERCIAL LICENSE. Lic.№: SLA QM0380024-CT183072-OP057524. https://campaign.optum.com/ content/optum/en.html

19. Orsi A., Sherman O., Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21 (6):767-769.

20. Ott B. R., Daiello L. A., Dahabreh I.J. et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 2015;30 (3):348-358. doi: 10.1007/s11606-014-3115-3.

21. Beydoun M. A., Beason-Held L. L., Kitner-Triolo M. H. et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health 2011;65 (11):949-957. doi: 10.1136/jech.2009.100826.

22. Trompet S., van Vliet P., de Craen A.J. et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010;257 (1):85-90. doi: 10.1007/s00415-009-5271-7.

23. Summers M.J., Oliver K. R., Coombes J. S. et al. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy 2007;27 (2):183-190.10.1592/phco.27.2.183

24. Macedo A. F., Taylor F. C., Casas J. P. et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014;12 (1):51. doi: 10.1186/1741-7015-12-51.

25. Rojas-Fernandes C. H., Goldstein L. B., Levey A. I. et al. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol 2014;8: S5 - S16. doi: 10.1016/j.jacl.2014.02.013.

26. Swiger K.J., Manalac R.J., Blumenthal R. S. et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013;88 (11):1213-1221. doi: 10.1016/j.mayocp.2013.07.013.

27. Okifuji A., Hare B. D. The association between chronic pain and obesity. J Pain Res 2015;8:399-408. doi: 10.2147/JPR.S55598.